Immunogenicity to cerliponase alfa, an enzyme replacement therapy for patients with CLN2 disease: results from a phase 1/2 study

被引：0
|
作者：
Cherukuri, Anu [1 ]
Cahan, Heather [1 ]
Van Tuyl, Andrea [1 ]
de Hart, Greg [1 ]
Slasor, Peter [1 ]
Bray, Laurie [1 ]
Henshaw, Josh [1 ]
Ajayi, Temitayo [1 ]
Jacoby, Dave [1 ]
O'Neill, Charles [1 ]
Schweighardt, Becky [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
D O I：
10.1016/j.ymgme.2016.11.064
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
55
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [31] Comparing developmental outcomes of children with CLN2 disease receiving cerliponase alfa to a natural history cohort
    Scherr, Jessica
    Berry-Kravis, Elizabeth
    de los Reyes, Emily
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S94 - S95
  • [32] Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease
    Hammon, Kevin
    de Hart, Greg
    Vuillemenot, Brian R.
    Kennedy, Derek
    Musson, Don
    O'Neill, Charles A.
    Katz, Martin L.
    Henshaw, Joshua W.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 1810 - 1821
  • [33] Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A 3 year update from an ongoing multicenter extension study
    Schulz, Angela
    Specchio, Nicola
    Gissen, Paul
    de los Reyes, Emily
    Cahan, Heather
    Slasor, Peter
    Jacoby, David
    Ajayi, Temitayo
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S133 - S133
  • [34] Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children younger than three years: Interim results from an ongoing clinical study
    Schulz, Angela
    de los Reyes, Emily
    Specchio, Nicola
    Gissen, Paul
    Slasor, Peter
    Bondade, Shailesh
    Jacoby, David
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S95 - S95
  • [35] Cerliponase alfa for treatment of CLN2 disease in a patient cohort including children <3 years old: Interim results from an ongoing clinical study
    Schulz, Angela
    de los Reyes, Emily
    Specchio, Nicola
    Gissen, Paul
    Slasor, Peter
    Bondade, Shailesh
    Cohen-Pfeffer, Jessica
    Jacoby, David
    EPILEPSIA, 2021, 62 : 32 - 33
  • [36] Persistent Treatment Effect Of Cerliponase Alfa In Children With CLN2 Disease: A 3 Year Update From An Ongoing Multicenter Extension Study
    Specchio, N.
    Schulz, A.
    Gissen, P.
    de los Reyes, E.
    Cahan, H.
    Slasor, P.
    Jacoby, D.
    Ajayi, T.
    EPILEPSIA, 2019, 60 : 157 - 157
  • [37] Intravitreal Cerliponase alfa slows the rate of retinal thinning in patients with CLN2 type Batten Disease: A first in man report
    Henderson, Robert
    Wawrzynski, James
    Martinez, Ana Rodriguez
    Bowman, Richard
    Whiteley, Rebecca
    Gan, Chin
    Harding, Louise
    Mortensen, Amanda
    Thompson, Dorothy
    Gissen, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [38] Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A > 4 year update from an ongoing multicenter extension study
    Schulz, Angela
    Specchio, Nicola
    Gissen, Paul
    de los Reyes, Emily
    Slasor, Peter
    Jacoby, David
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S145 - S145
  • [39] Deep phenotyping proteomics analysis of CSF from CLN2 patients undergoing enzyme replacement therapy
    Iwan, Katharina
    Doykov, Ivan D.
    Mills, Kevin
    Mole, Sara E.
    Zancolli, Marta
    Mills, Philippa
    Lee, Laura
    Gissen, Paul
    Heywood, Wendy E.
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S79 - S80
  • [40] Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children under 3 years of age
    Schulz, Angela
    Reyes, Emily C. de Los
    Specchio, Nicola
    Gissen, Paul
    Slasor, Peter
    Bondade, Shailesh
    Pfeffer, Jessica L. Cohen
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
12345